Get the Stockscreener App
1.025
0.97%
-0.01
Tuhura Biosciences Inc stock is traded at $1.025, with a volume of 563.22K.
It is down -0.97% in the last 24 hours and down -54.04% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$1.035
Open:
$1.07
24h Volume:
563.22K
Relative Volume:
2.08
Market Cap:
$57.89M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-47.16%
1M Performance:
-54.04%
6M Performance:
-60.88%
1Y Performance:
-80.95%
1-Day Range:
$1.00
$1.07
1-Week Range:
$0.972
$2.02
52-Week Range:
$0.972
$5.6084
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.025 | 58.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen - Defense World
TuHURA Biosciences provides corporate update after $15.6M financing By Investing.com - Investing.com South Africa
TuHURA Biosciences (NASDAQ: HURA) outlines 2026 trial milestones after $15.6M raise - Stock Titan
TuHURA Biosciences Announces Securities Purchase Agreement - TipRanks
Big Drops For Top Wealth, TuHURA Biosciences, And AutoZone - Finimize
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More - ts2.tech
TuHURA Biosciences announces $15.6M registered direct offering - TipRanks
TuHURA Biosciences plunges after $15.6 million direct stock deal - TradingView — Track All Markets
TuHURA Biosciences announces $15.6 million registered direct offering - Investing.com
TuHURA Biosciences announces $15.6 million registered direct offering By Investing.com - Investing.com Nigeria
Sabio Holdings (TSXV: SBIO, OTCQB: SABOF) inks Creator TV pact with MADCOOL Media - Stock Titan
Liminatus Pharma (LIMN) Competitors and Alternatives 2025 - MarketBeat
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor as A New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors At the 57Th Annual Meeting and Exposition - marketscreener.com
TuHURA Biosciences presents research on potential role of DOR at ASH - TipRanks
TuHURA Biosciences presents data on DOR’s role in cancer immunotherapy By Investing.com - Investing.com South Africa
TuHURA Biosciences presents data on DOR’s role in cancer immunotherapy - Investing.com
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition - PR Newswire
Tuhura Biosciences amends loan agreement, secures full $3M - MSN
TuHURA Biosciences (HURA) Stock Analysis Report | Financials & Insights - Benzinga
TuHURA Biosciences (NASDAQ:HURA) Rating Increased to Hold at Wall Street Zen - MarketBeat
TuHURA Biosciences Amends Loan Agreement, Secures Full $3M - TipRanks
Can TuHURA Biosciences Inc. (PL3) stock deliver double digit returnsJuly 2025 Technicals & Verified Swing Trading Watchlists - Newser
What drives TuHURA Biosciences Inc stock pricePortfolio Diversification Tips & Superior Capital Growth - earlytimes.in
Will TuHURA Biosciences Inc. (PL3) stock deliver compounding returnsMarket Performance Summary & Fast Moving Stock Watchlists - Newser
Will TuHURA Biosciences Inc. stock reach all time highs in 2025July 2025 Opening Moves & Intraday High Probability Alerts - Newser
Is TuHURA Biosciences Inc. (PL3) stock a buy during volatile markets2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Can TuHURA Biosciences Inc. (PL3) stock sustain revenue momentumCPI Data & Free Community Supported Trade Ideas - Newser
Why TuHURA Biosciences Inc. (PL3) stock benefits from AI revolutionMarket Performance Summary & Proven Capital Preservation Tips - Newser
Can TuHURA Biosciences Inc. (PL3) stock beat analyst consensusEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Stock Market Recap: Can TuHURA Biosciences Inc. stock weather global recessionEntry Point & Fast Gain Stock Trading Tips - moha.gov.vn
Top investors say TuHURA Biosciences Inc (HURA) ticks everything they need - Setenews
TuHURA Biosciences shelf registration statement becomes effective By Investing.com - Investing.com Australia
TuHURA Biosciences’ Shelf Registration Statement Effective - TipRanks
TuHURA Biosciences shelf registration statement becomes effective - Investing.com
TuHURA Biosciences Announces Effective Shelf Registration Statement - TradingView
TuHURA Biosciences (NASDAQ:HURA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Equities Analysts Offer Predictions for HURA FY2025 Earnings - MarketBeat
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Zacks Small Cap Issues Optimistic Forecast for HURA Earnings - Defense World
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of “Buy” from Brokerages - Defense World
How TuHURA Biosciences Inc. stock performs in weak economyJuly 2025 Momentum & Fast Entry High Yield Stock Tips - newser.com
Is TuHURA Biosciences Inc. stock safe for conservative investorsJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Can TuHURA Biosciences Inc. (PL3) stock hit consensus price targets2025 Performance Recap & Technical Pattern Based Signals - newser.com
Why TuHURA Biosciences Inc. stock is trending among retail tradersJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Is it too late to sell TuHURA Biosciences Inc.2025 Big Picture & Weekly High Return Opportunities - newser.com
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):